Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

TRABD Inhibitors

TRABD inhibitors are a class of chemical compounds designed to specifically target the TRABD protein, a member of the TRAB domain-containing family, and inhibit its biological function. These inhibitors typically bind to the active site of the TRABD protein, where they prevent its natural substrates or ligands from interacting with the protein. This inhibition blocks the normal biochemical processes facilitated by TRABD, altering the protein's role in cellular pathways. In some cases, TRABD inhibitors can bind to allosteric sites on the protein, which are located away from the active site. By binding to these allosteric regions, inhibitors can induce conformational changes in the protein, leading to a decrease or cessation of its functional activity. The interaction between TRABD inhibitors and the protein is mediated by various non-covalent forces, such as hydrogen bonding, hydrophobic contacts, van der Waals forces, and electrostatic interactions, which stabilize the inhibitor-protein complex and ensure effective inhibition.

The structural design of TRABD inhibitors is highly diverse, allowing for flexibility in their interaction with different regions of the TRABD protein. These inhibitors often incorporate functional groups like hydroxyl, amine, or carboxyl groups, which facilitate specific interactions with key residues within the TRABD protein's binding pocket. Aromatic rings and heterocyclic structures are frequently present in these inhibitors to enhance hydrophobic interactions with non-polar regions of the protein, increasing their binding affinity. Additionally, the physicochemical properties of TRABD inhibitors, such as molecular weight, lipophilicity, solubility, and polarity, are optimized to ensure stability and effectiveness in various biological environments. Hydrophobic regions within the inhibitor may interact with non-polar regions of the protein, while polar groups enhance solubility and promote hydrogen bonding with polar residues in the TRABD protein. By balancing these structural and physicochemical properties, TRABD inhibitors can be fine-tuned to achieve specific and effective modulation of the protein's activity in different biological contexts.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$74.00
$243.00
$731.00
$2572.00
$21848.00
53
(3)

Binds to DNA and inhibits transcription elongation by RNA polymerase, potentially decreasing expression of "TraB domain containing".

α-Amanitin

23109-05-9sc-202440
sc-202440A
1 mg
5 mg
$269.00
$1050.00
26
(2)

Inhibits RNA polymerase II, which could lead to reduced mRNA synthesis and lower levels of "TraB domain containing" protein.

Triptolide

38748-32-2sc-200122
sc-200122A
1 mg
5 mg
$90.00
$204.00
13
(1)

Alters transcriptional activity, potentially reducing the expression of the "TraB domain containing" protein.

Cordycepin

73-03-0sc-203902
10 mg
$101.00
5
(1)

Shortens RNA poly(A) tails, possibly decreasing mRNA stability and expression of "TraB domain containing".

DRB

53-85-0sc-200581
sc-200581A
sc-200581B
sc-200581C
10 mg
50 mg
100 mg
250 mg
$43.00
$189.00
$316.00
$663.00
6
(1)

Inhibits RNA polymerase II activation, potentially decreasing "TraB domain containing" protein levels.

Ribavirin

36791-04-5sc-203238
sc-203238A
sc-203238B
10 mg
100 mg
5 g
$63.00
$110.00
$214.00
1
(1)

Induces mutations in RNA and DNA, possibly leading to decreased expression of "TraB domain containing" protein.

Mitomycin C

50-07-7sc-3514A
sc-3514
sc-3514B
2 mg
5 mg
10 mg
$66.00
$101.00
$143.00
85
(5)

Forms DNA crosslinks, potentially preventing transcription and reducing "TraB domain containing" protein expression.

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$176.00
$426.00
43
(3)

Intercalates DNA and interferes with topoisomerase II, potentially reducing expression of "TraB domain containing".

Camptothecin

7689-03-4sc-200871
sc-200871A
sc-200871B
50 mg
250 mg
100 mg
$58.00
$186.00
$94.00
21
(2)

Inhibits DNA topoisomerase I, potentially leading to decreased transcription of the "TraB domain containing" gene.

Rocaglamide

84573-16-0sc-203241
sc-203241A
sc-203241B
sc-203241C
sc-203241D
100 µg
1 mg
5 mg
10 mg
25 mg
$275.00
$474.00
$1639.00
$2497.00
$5344.00
4
(1)

Inhibits translation initiation, which could reduce the levels of "TraB domain containing" protein.